PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项前瞻性研究，以评估目前处方的抗逆转录病毒药物和这些药物的相互作用组合在怀孕的艾滋病毒感染的妇女的药代动力学。受试者可在大于或小于20周妊娠时入组。受试者必须入组P1025，并且目前正在接受与研究相关的药物。本方案的主要目的是描述目前用于妊娠HIV感染女性临床护理的选定抗逆转录病毒药物在妊娠期间的PK参数，并确定这些抗逆转录病毒药物的治疗性给药方案是否在妊娠期间产生足够的药物释放，与a）非妊娠成人的历史数据和B）研究队列中相同女性在产后期间相比。 PACTG P1026 V3

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a propective study to evaluate the pharmacokinetics of currently prescribed antiretroviral drugs and interacting combinations of these drugs in pregnant HIV-infected women. Subjects can enroll at greater or less than 20 weeks gestation. Subjects must be enrolled in P1025 and currently receiving drugs pertinent to the study. The primary objective of this protocol is to describe the PK parameters during pregnancy of selected antiretroviral drugs currently used in the clinical care of pregnant HIV-infected women, and to determine if therapeutic dosing regimes of these antiretroviral drugs produce adequate drug expsoure during the pregnancy compared to a) historical data from non-pregnant adults, and b) the same women in the study cohorts during the postpartum period. PACTG P1026 V3